Does Early Trutakna Sales Change The Bull Case For Vera Therapeutics (VERA)?
- Vera Therapeutics reported its first commercial revenue from TRUTAKNA in the third quarter of 2026, with US$10.3 million in sales, alongside a quarterly net loss of US$93.71 million and a basic loss per share of US$1.30.
- TRUTAKNA’s early U.S. launch shows about 700 Patient Start Forms and positive two year ORIGIN 3 data, while Vera Therapeutics is already pursuing full FDA approval and planning a European filing.
- This article examines how Vera Therapeutics’ investment narrative is shaped by TRUTAKNA’s first commercial revenue and ORIGIN 3 efficacy data.
Vera Therapeutics Investment Narrative Recap
For Vera Therapeutics, the big picture investors need to consider is that TRUTAKNA can potentially move from early U.S. adoption into a durable kidney disease franchise, while the broader atacicept platform adds future indications. The latest quarter supports that narrative by generating the first US$10.3 million of revenue and presenting two-year ORIGIN 3 efficacy data for the drug.
The near-term catalyst is the push toward full FDA approval and the planned European filing, both linked to the ORIGIN 3 dataset. The most immediate risk is the widening net loss, at US$93.71 million in Q3 and US$324.22 million over nine months, as commercial and R&D spending remain elevated.
The announcement that Vera Therapeutics posted its first TRUTAKNA sales in the third quarter of 2026 is central to the story. Roughly 700 Patient Start Forms and US$10.3 million in partial-quarter revenue provide an early indication of prescriber interest and payer access, rather than relying solely on a theoretical market model.
The same update noted the supplemental Biologics License Application for full U.S. approval and plans for a European submission in early 2027. These regulatory timelines define the main operational catalysts. At the same time, the current losses and premium P/B valuation keep execution on uptake, pricing, and cost control in sharp focus for anyone following the stock.
Vera Therapeutics’ current analyst narrative points to forecast revenue of US$821.0 million and earnings of US$108.1 million by 2029. This implies a very large step up from effectively no sales today and a move in earnings of about US$510 million, from a loss of US$401.9 million to the projected profit level.
Uncover why Vera Therapeutics' fair value indicates a 160% potential upside to its current price, which could materialize more quickly than many investors expect.
Exploring Other Perspectives
Here is where the alternate view bites. The most cautious analysts focused on TRUTAKNA launch risk and were only modeling about US$23 million of 2026 revenue and roughly US$386.8 million by 2029 before this earnings print. That is far below the US$821.0 million consensus path, which shows how widely opinions on Vera Therapeutics can differ.
Explore 2 other Vera Therapeutics fair value estimates, including one that suggests it could be worth just $73.07!
Form Your Own Verdict
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your Vera Therapeutics research is our analysis highlighting 2 key rewards that could impact your investment decision.
- See our latest analysis for Vera Therapeutics. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Vera Therapeutics' overall financial health at a glance.
Looking For More Ideas Beyond Vera Therapeutics?
If you want to pressure test your thesis on Vera Therapeutics and broaden your opportunity set at the same time, the Simply Wall St Screener can surface other stocks that match different risk, income, and quality profiles in just a few minutes.
- For investors who care most about balance sheet strength and fundamental resilience, start with this curated list of solid balance sheet and fundamentals (24 results). It can help you focus on sturdier businesses first.
- If you want potential mispricing opportunities where quality and valuation intersect, scan through a hand picked 39 high quality undervalued stocks that may merit a closer look.
- Income focused readers who like to get paid while they wait can review a targeted 8 dividend fortresses that screens for higher yielding dividend payers.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com